Blood GFAP as an emerging biomarker in brain and spinal cord disordersAhmed Abdelhak, Hayrettin Tumani, Matteo Foschi et al.|Nature Reviews Neurology|2022Cited by 809
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trialBruce Cree, Eliezer Katz, Jeffrey L. Bennett et al.|The Lancet|2019Cited by 722
Multiple sclerosis progression: time for a new mechanism-driven frameworkTanja Kuhlmann, Emmaunelle Waubant, Marcello Moccia et al.|The Lancet Neurology|2022Cited by 624
Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysisAxel Petzold, Bernhard Hemmer, Laura J. Balcer et al.|The Lancet Neurology|2017Cited by 572
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosisSergio E. Baranzini, Jorge R. Oksenberg, Joanne Wang et al.|Human Molecular Genetics|2008Cited by 479